Revolution Medicines develops targeted oncology therapies, including treatments for RAS-addicted cancers.
Hom said Revolution Medicines' molecular-glue therapy increased median survival in second-line metastatic pancreatic cancer from roughly seven to thirteen months, with fewer serious adverse events, and could become a baseline for combination therapies.